Drugs / lulizumab pegol
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03058822 | Jan → Mar 2017 | — | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04066114 | Dec 2019 → Sep 2023 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04903054 | Jan → Sep 2022 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 2 | NCT02843659 | Oct 2016 → Jul 2017 | Sjogren syndrome | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT02265744 | Nov 2014 → Oct 2017 | lupus erythematosus | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lulizumab pegol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04066114 ↗ |
| Known as | BMS-931699 | “Pharmacokinetics of Lulizumab (BMS-931699) From Prefilled Syringe” NCT03058822 ↗ |
| Known as | Lulizumab | “Pharmacokinetics of Lulizumab (BMS-931699) From Prefilled Syringe” NCT03058822 ↗ |
| Action | Inhibit | “Selective CD28 Blockade With Lulizumab” NCT04903054 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3137354 ↗ |
| Route | Subcutaneous | “12.5mg subcutaneous (SC) injection Weekly dosing” NCT02265744 ↗ |
| Target | CD28 | “lulizumab pegol and tocilizumab act on specific molecules (specifically CD28 and interleukin 6, respectively)” NCT04066114 ↗ |